These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
195 related items for PubMed ID: 23801137
1. Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y, Miyachi Y, Matsubara T, Yanagita M, Haga H, Takaori-Kondo A. J Clin Exp Hematop; 2013; 53(1):69-77. PubMed ID: 23801137 [Abstract] [Full Text] [Related]
2. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role? Bhanvadia V, Shet T, Rao V, Epari S, Gujral S, Jain H, Bagal B, Sengar M. Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624 [Abstract] [Full Text] [Related]
3. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, Miki M, Sakai T, Kawanami T, Sawaki T, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Umehara H. J Clin Exp Hematop; 2013; 53(1):79-85. PubMed ID: 23801138 [Abstract] [Full Text] [Related]
4. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233 [Abstract] [Full Text] [Related]
5. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis. Awano N, Inomata M, Kondoh K, Satake K, Kamiya H, Moriya A, Ando T, Kumasaka T, Takemura T, Takeuchi K, Ikushima S. Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151 [Abstract] [Full Text] [Related]
6. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y. J Clin Exp Hematop; 2013; 53(1):57-61. PubMed ID: 23801135 [Abstract] [Full Text] [Related]
9. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, Kadowaki N, Takaori-Kondo A. Intern Med; 2013 Apr; 52(13):1503-7. PubMed ID: 23812199 [Abstract] [Full Text] [Related]
10. Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, Orita Y, Nakao S, Yoshino T. J Clin Exp Hematop; 2013 Apr; 53(1):87-93. PubMed ID: 23801139 [Abstract] [Full Text] [Related]
11. [Dyspnoea, cough and B symptoms in a 40-year-old woman]. Wolfensberger A, Benz R, Russi EW, Tinguely M, Keller C, Gerber B. Internist (Berl); 2013 Aug; 54(8):1011-5. PubMed ID: 23836253 [Abstract] [Full Text] [Related]
12. A retrospective study of 44 patients with head and neck Castleman's disease. Wang T, Chen X, Chen W, Shi L, Liu J. Eur Arch Otorhinolaryngol; 2022 May; 279(5):2625-2630. PubMed ID: 34480599 [Abstract] [Full Text] [Related]
13. [Clinical Features and Prognosis of Patients with Castleman's Disease]. Huang XJ, Zhang XL, Wei XF, Liang XQ, Fu Y, Zhao YY, Li QF, Zhang QK, Feng YF. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):135-140. PubMed ID: 36765490 [Abstract] [Full Text] [Related]
14. A case of multicentric castleman's disease of mixed-type, which showed constellation of symptoms, i.e., thrombocytopenia, anasarca, anemia, fever, myelofibrosis, and lymphadenopathy. Awano N, Inomata M, Sonoda Y, Kondoh K, Ono R, Moriya A, Ando T, Kumasaka T, Takemura T, Takeuchi K, Ikushima S. J Clin Exp Hematop; 2013 Feb; 53(1):101-5. PubMed ID: 23801141 [No Abstract] [Full Text] [Related]
15. Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. Ebisawa K, Shimura A, Honda A, Masamoto Y, Nakahara F, Kurokawa M. Leuk Lymphoma; 2021 Mar; 62(3):614-619. PubMed ID: 33076723 [Abstract] [Full Text] [Related]
19. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Murakami M, Johkoh T, Hayashi S, Ohshima S, Mizuki M, Nakatsuka SI, Tomobe M, Kuroyanagi K, Nakasone A, Nishimoto N. Mod Rheumatol; 2020 Sep; 30(5):843-851. PubMed ID: 31829070 [Abstract] [Full Text] [Related]
20. Multicentric Castleman's disease associated with inherited epidermolysis bullosa. Kawakami Y, Nishibu A, Kikuchi S, Ohtsuka M, Nakamura K, Nozawa Y, Abe M, Iwatsuki K, Kaneko F. J Dermatol; 2003 Sep; 30(9):689-93. PubMed ID: 14578560 [Abstract] [Full Text] [Related] Page: [Next] [New Search]